US Patent

US10548909 — Co-crystals of tramadol and coxibs

Method of Use · Assigned to Esteve Pharmaceuticals SA · Expires 2030-04-19 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects co-crystals of tramadol and coxibs, such as Celebrex, for use in treating pain.

USPTO Abstract

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.

Drugs covered by this patent

Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3244`	—	Celebrex

Patent Metadata

Patent number: US10548909
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-19
Drug substance claim: No
Drug product claim: No
Assignee: Esteve Pharmaceuticals SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.